BIOCHING CAPITAL
VC Fund
Longgang, China
BIOCHING CAPITAL is an investment management firm.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries BIOCHING CAPITAL invests in
Stages BIOCHING CAPITAL invests in
Countries BIOCHING CAPITAL invests in
Round sizes
Round size
- Angel
- $425k–$15M
- Series A
- $14M–$14M
Investment Focus
Industry
- Medical 8 (40%)
- Medical Device 8 (40%)
- Biotechnology 7 (35%)
- Health Care 6 (30%)
- Genetics 2 (10%)
Stage
- Angel 7 (35%)
- Series A 7 (35%)
- Seed 4 (20%)
- Funding Round 2 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lunke Medical
|
Lunke Medical focuses on the research, development, production, and sales of medical devices, with particular strength and expertise in high-pressure technologies. The company is committed to delivering safe, reliable, and innovative solutions by combining advanced engineering, strict quality control, and continuous technological advancement tomeet the evolving needs of the medical industry. | Series A / Jan 15, 2026 | |
Taose Tuantuan
|
Taose Tuantua is a sex toy company that primarily offers TAOSETT sex toy academy and exquisite sex toy community store services. | Seed / Nov 11, 2024 | |
Qinglan Jichuang
|
Qinglan Jichuang is a domestic high-performance intelligent endoscope innovative enterprise. | Seed / Oct 28, 2024 | |
Weimai Medical
|
Weimai Medical is an all-inclusive resource for minimally invasive and non-invasive energy medicine solutions. | $14.2M / Series A / Sep 25, 2024 | |
|
Thorough Future
|
Using big data and artificial intelligence to provide pathology images with intelligent discriminations, diagnosis, prediction. | $13.9M / Series A / Jun 06, 2024 | |
Aoli Biotechnology
|
Aoli Biotechnology is a biopharmaceutical oral delivery technology provider. Aoli Biotechnology focuses on research into macromolecule oral delivery technology and has developed a number of world-leading excipient technology patents, including soteria and phloral technology. | Seed / Jan 29, 2024 | |
Salus BioMed
|
Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products. | Series A / Dec 01, 2023 | |
Yinghe Brain Science
|
Yinghe Brain Science is a neuromodulation platform developer | $14.7M / Angel / Jan 21, 2023 | |
Dameng Bio
|
Dameng Bio is a medical firm specializing in the R&D, production, and service of tumor pathological diagnostic instruments and reagents. | Series A / Dec 17, 2021 | |
|
Seppo Biotechnology
|
Seppo Biotechnology is a high-tech enterprise that develops mass spectrometry instruments and consumables. | Angel / Jan 01, 2021 | |
| See all 20 investments → | |||
Co-Investors
Qianhai Fund of Funds
2 deals together
Qiming Venture Partners
2 deals together
ASBV
1 deal together
BioTrack Capital
1 deal together
BrightGene
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does BIOCHING CAPITAL invest in?
BIOCHING CAPITAL invests primarily in Medical, Medical Device and Biotechnology startups, most often at Angel and Series A stage. Most of the 20 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BIOCHING CAPITAL's check size?
BIOCHING CAPITAL typically joins rounds of $425k–$15M at Angel and $14M–$14M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BIOCHING CAPITAL participates in.
When did BIOCHING CAPITAL last invest?
The most recent investment recorded for BIOCHING CAPITAL closed in Jan 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
